Curetis Archives

Latest Posts

News and Trends 13 Nov 2015

Curetis Molecular Diagnostics IPO Exceeds Expectations

The Southern German Med-tech for infectious disease biotech, Curetis, has sold shares up to a value of €40M, which is 10 million above its initial target, despite a lower ranged Offer price. Curetis have developed a molecular diagnostics system for hospital acquired infections (such as MRSA and Pneumonia). Their Unyvero system is a piece of […]

November 13, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

Curetis AG, the molecular diagnostics company from the Stuttgart area (Germany), has now announced its launch of an initial public offering (IPO). Previously, this biotech has raised €63.5M to develop its Unyvero Platform for testing infectious disease, including Pneumonia and biomarkers in antibiotic resistance. This new IPO aims to further commercialize this system and expand […]

October 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 5 Dec 2014

Forbion Capital Partners: a Leading European Biotech VC is rising!

Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare technologies, sold PneumRx of its portfolio, to BTG plc, the UK-based specialist healthcare company for an initial cash consideration of €186M and up to €199M in performance-related future milestone payments. PneumRx is a growing interventional pulmonology business which owns, manufactures and distributes the RePneu Coil […]

December 5, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 27 Nov 2014

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

Curetis AG, a developer of next-level molecular diagnostic solutions, has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. Curetis is a young, dynamic and creative molecular diagnostics company. They are specialized in the diagnosis of severe infectious diseases in hospitalized patients. The company helps to combat […]

November 27, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us